跳至主要内容
临床试验/NCT02105168
NCT02105168Unknown不适用

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment in Patients With Lung Cancer or Melanoma

Gustave Roussy, Cancer Campus, Grand Paris2 个研究点 分布在 1 个国家目标入组 2,200 人开始时间: 2009年7月最近更新:
适应症

试验速览

阶段
不适用
入组人数
2,200
试验地点
2
主要终点
Mutation rate on tumorous material

研究概览

简要总结

Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next generation sequencing to identify rare mutations and assessed their predictive value.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Screening
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Cytological or histological diagnosis of SCLC, NSCLC or melanoma
  • Patients age >/= 18 years old
  • Indication of treatment using platinum salts for lung cancer except for patient with NSCLC treated by surgery for whom platinum salts is not indicated
  • If a biopsy is proposed, lesion lust be easily accessible
  • Signed informed consent

排除标准

  • Patients unable to follow the protocol
  • Consent refusal

结局指标

主要结局

Mutation rate on tumorous material

时间窗: Assessed at the time of inclusion

Assessed at the time of inclusion using tumorous material used for diagnosis

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验